ATAI Life Sciences N.V (ATAI) stock forecast: Can it reach its 52-week high of $3.35

ATAI Life Sciences N.V [ATAI] stock is trading at $3.53, up 9.29%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ATAI shares have gain 29.78% over the last week, with a monthly amount glided 51.50%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

ATAI Life Sciences N.V [NASDAQ: ATAI] stock has seen the most recent analyst activity on November 18, 2024, when H.C. Wainwright reiterated its Buy rating and also revised its price target to $10 from $15. Previously, Maxim Group upgraded its rating to Buy on April 03, 2024, and kept the price target unchanged to $6. On November 01, 2022, Loop Capital initiated with a Buy rating and assigned a price target of $18 on the stock. Maxim Group started tracking the stock assigning a Buy rating and suggested a price target of $25 on November 30, 2021. ROTH Capital initiated its recommendation with a Buy and recommended $32 as its price target on November 11, 2021. H.C. Wainwright started tracking with a Buy rating for this stock on October 18, 2021, and assigned it a price target of $40. In a note dated September 01, 2021, Jefferies initiated an Buy rating and provided a target price of $27 on this stock.

ATAI Life Sciences N.V [ATAI] stock has fluctuated between $1.03 and $3.35 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. ATAI Life Sciences N.V [NASDAQ: ATAI] shares were valued at $3.53 at the most recent close of the market. An investor can expect a potential return of 41.64% based on the average ATAI price forecast.

Analyzing the ATAI fundamentals

ATAI Life Sciences N.V [NASDAQ:ATAI] reported sales of 0.33M for the trailing twelve months, which represents a growth of 8538.89%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -53.12%, Pretax Profit Margin comes in at -80.14%, and Net Profit Margin reading is -79.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is -1.02 and Total Capital is -0.59. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.

Ratios To Look Out For

For context, ATAI Life Sciences N.V’s Current Ratio is 4.07. As well, the Quick Ratio is 4.07, while the Cash Ratio is 1.69. Considering the valuation of this stock, the price to sales ratio is 2147.45, the price to book ratio is 4.64.

Transactions by insiders

Recent insider trading involved SAHIL KIRPEKAR, Officer, that happened on Jul 02 ’25 when 83332.0 shares were purchased. Officer, SAHIL KIRPEKAR completed a deal on Jul 01 ’25 to buy 0.11 million shares. Meanwhile, Officer SAHIL KIRPEKAR bought 80000.0 shares on Jun 04 ’25.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.